

DCF Psychotropic Medication Advisory Committee
Meeting Minutes
December 2, 2022, 1:00 PM

PRESENT via Video Conference: Paul Rao, MD; Margaret Rudin, APRN, PhD; Brian Keyes, MD; Carissa Patsky-Pomerleau, MD; Naomi Libby, MD; Hilary Klein, MD; Dielka Brutus, APRN; Angela Ojide, APRN; Roumen Nikolov, MD; David Aversa, MD; Rosina Bandanza, MD; Nicole Taylor, MD

1. The meeting was held remotely via Zoom; Dr. Rao called the meeting to order at 1:05pm.
2. The next meeting is scheduled for March 3rd, 2022, from 1pm – 2:30pm via Zoom
3. Minutes: The minutes of the September 2022 meeting were reviewed and approved.
4. Announcements: There were no announcements.
5. Medication therapeutic class review and discussion:

--The antipsychotic class was discussed. The existing monitoring guidelines were reviewed. There was discussion about best practices with respect to obtaining a prolactin level at baseline with certain antipsychotics. The challenges of managing asymptomatic prolactin elevations, and of inheriting the care of youth in DCF care with unclear histories, was discussed at length. It was discussed that it would be best for DCF guidelines on prolactin monitoring to comport with the positions of professional organizations and current data. It was agreed that these positions, as well as any current research on the utility of obtaining baseline prolactin, would be reviewed for the next meeting.

--Monitoring for the emergence of metabolic syndrome in youth prescribed antipsychotics was discussed. Early adversities including chaotic rearing and subsequent placement in foster care were discussed as risk factors for poor health outcomes, including obesity, independent of antipsychotic use.

--The existing frequency of lipid and glucose monitoring with typical versus atypical antipsychotics was discussed briefly, and it was recommended that this be a topic for ongoing discussion, with possible changes to the protocol depending on the latest research and best practice standards.

--A recommendation was made to review brexipiprazole (Rexulti) for inclusion on the approved medication list as it has recently been FDA approved for use in adolescents ages 13-17 with schizophrenia.

6. New Business:
 - review of droperidol for inclusion on the approved medication list: A systematic review of the use of droperidol in pediatric emergency settings (Ramsden et al, [Academic Emergency Medicine](#), 2022) for the treatment of acute agitation was discussed. The potential benefits of droperidol for acute agitation, including the possibility of more rapid efficacy, the possibility of less need for co-administration of other anti-agitation medicine or repeat dosing, were discussed at length. There were several shortcomings discussed, including the small number of studies included in the review, the lack of controlled or comparative studies, and the lack of availability of oral dosing. A

recommendation was made to obtain more evidence in the literature before consideration of approval, but that in the meantime, this could, like other anti-agitation medicines, be administered on an emergency basis to prevent harm to self or others as a result of acute agitation

--PMAC position statement on Medication Assisted Treatment for substance use disorders: A first draft of a position statement was circulated prior to the meeting and reviewed and discussed. A recommendation was made to convert the draft to a document that could be edited in real time by the group, with a plan for review at the next meeting.

7. Standing items: none

8. Other as time allows: none

9. Dr. Rao adjourned the meeting at 2:15 PM.

Respectfully submitted: Paul Rao, MD